DICE Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $550.67 Mil.
During the past 12 months, DICE Therapeutics's average Total Assets Growth Rate was 9.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 63.10% per year.
During the past 4 years, DICE Therapeutics's highest 3-Year average Total Assets Growth Rate was 63.10%. The lowest was 63.10%. And the median was 63.10%.
The historical data trend for DICE Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
DICE Therapeutics's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DICE Therapeutics (NAS:DICE) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
DICE Therapeutics's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
DICE Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of DICE Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
DICE Therapeutics (DICE Therapeutics) Business Description
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DICE has been successfully added to your 